The bill, HB 1809, establishes a medical use program for psilocybin under the Department of Health and Human Services (DHHS) to provide therapeutic treatment for patients with serious conditions such as treatment-resistant depression, post-traumatic stress disorder, and substance use disorders. It introduces a new chapter, RSA 126-ZZ, which includes definitions for key terms like "provider," "qualified patient," and "qualifying condition." The DHHS will be responsible for approving providers and producers of psilocybin, maintaining a public list of these entities, and collecting data to evaluate the program's effectiveness. The bill also creates a medical psilocybin advisory board to oversee the program, which will consist of various stakeholders, including medical professionals and a qualifying patient.

The advisory board is tasked with determining the program's readiness for implementation within two years of the bill's enactment; if it fails to do so, the bill will not take effect. While the bill does not allocate funding or authorize new positions, it is projected to incur indeterminable expenditures, with the DHHS estimating initial administrative costs of $250,000 in the first year and subsequent costs of $224,000 and $236,000 in the following two years. The bill introduces new legal language related to the medical use of psilocybin and the establishment of the advisory board, but it does not specify any deletions from current law. The program will take effect 30 days after the advisory board certifies its readiness.